Literature DB >> 8707409

Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer.

U Kaiser1, J Hofmann, M Schilli, B Wegmann, U Klotz, S Wedel, A K Virmani, E Wollmer, D Branscheid, A F Gazdar, K Havemann.   

Abstract

Female gender is a significant independent favorable prognostic factor in lung cancer. To study the possible role of sex hormones in lung cancer, the expression of sex-steroid receptors and the glucocorticoid receptor was investigated in 29 lung-cancer cell lines stemming from small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) by means of immunocytochemistry, ligand-binding assays and RNA expression via polymerase chain reaction. In at least 2 methods of investigation, NSCLC cell lines showed a low expression of estrogen receptor in 6, progesterone receptor in 13 and androgen receptor in 12 out of 17 cases examined; sex-steroid-receptor expression was virtually absent in SCLC cell lines. The glucocorticoid receptor was expressed in all 29 cell lines studied. Additionally, 52 tumor samples from primary lung cancer were investigated for their receptor expression by means of immunohistochemistry. Among patients with primary lung-cancer sex-steroid-receptor expression in tumor biopsies was detected most frequently in female patients (in 69% of 16 cases, vs. 42% of 36 tumors from men) and in patients with adenocarcinoma. Further research will focus on these subgroups. Immunohistology is a feasible method of studying steroid-receptor expression in lung cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707409     DOI: 10.1002/(SICI)1097-0215(19960729)67:3<357::AID-IJC9>3.0.CO;2-Q

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  38 in total

1.  Targeting the estrogen pathway for the treatment and prevention of lung cancer.

Authors:  Timothy F Burns; Laura P Stabile
Journal:  Lung Cancer Manag       Date:  2014-02-01

2.  The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.

Authors:  Nadiyah Kazmi; Diana C Márquez-Garbán; Lilia Aivazyan; Nalo Hamilton; Edward B Garon; Lee Goodglick; Richard J Pietras
Journal:  Lung Cancer Manag       Date:  2012-12

Review 3.  Estrongenic steroid hormones in lung cancer.

Authors:  Jill M Siegfried; Laura P Stabile
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

4.  Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumors.

Authors:  Yiyang Li; Cheng Huang; Tamar Kavlashvili; Abby Fronk; Yuping Zhang; Yang Wei; Donghai Dai; Eric J Devor; Xiangbing Meng; Kristina W Thiel; Kimberly K Leslie; Shujie Yang
Journal:  Am J Cancer Res       Date:  2020-06-01       Impact factor: 6.166

5.  Sex Hormones and Lung Inflammation.

Authors:  Jorge Reyes-García; Luis M Montaño; Abril Carbajal-García; Yong-Xiao Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Smoking out reproductive hormone actions in lung cancer.

Authors:  Jill M Siegfried
Journal:  Mol Cancer Res       Date:  2014-01-07       Impact factor: 5.852

7.  Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women.

Authors:  Michele L Cote; Wonsuk Yoo; Angela S Wenzlaff; Geoffrey M Prysak; Susan K Santer; Gina B Claeys; Alison L Van Dyke; Susan J Land; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2009-01-27       Impact factor: 4.944

8.  Glucocorticoid receptor (GR) immunohistochemical expression is correlated with cell cycle-related molecules in human colon cancer.

Authors:  Stamatios Theocharis; Gregorios Kouraklis; Alexandra Margeli; Emmanuel Agapitos; Sotirios Ninos; Gabriel Karatzas; Antonios Koutselinis
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

9.  Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.

Authors:  Maria G Raso; Carmen Behrens; Matthew H Herynk; Suyu Liu; Ludmila Prudkin; Natalie C Ozburn; Denise M Woods; Ximing Tang; Reza J Mehran; Cesar Moran; J Jack Lee; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

10.  Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience.

Authors:  Katsuyuki Hotta; Katsuyuki Kiura; Nagio Takigawa; Shoichi Kuyama; Yoshihiko Segawa; Toshiro Yonei; Kenichi Gemba; Keisuke Aoe; Takuo Shibayama; Keisuke Matsuo; Haruhito Kamei; Yoshiro Fujiwara; Akihiko Bessho; Tomonori Moritaka; Keisuke Sugimoto; Masahiro Tabata; Hiroshi Ueoka; Mitsune Tanimoto
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.